OncoMatch/Clinical Trials/NCT06765161
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Is NCT06765161 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies efgartigimod administration for myasthaenia gravis.
Treatment: efgartigimod administration — This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: intravenous immunoglobulin — chronic regular treatment for myasthenia gravis for the past year or more
Receiving chronic regular IVIG treatments for myasthenia gravis for the past year or more
Cannot have received: anti-CD20 antibody (rituxan)
previous rituxan or eculizumab treatment or plasma exchange within the past six months
Cannot have received: C5 complement inhibitor (eculizumab)
previous rituxan or eculizumab treatment or plasma exchange within the past six months
Cannot have received: plasma exchange
previous rituxan or eculizumab treatment or plasma exchange within the past six months
Cannot have received: surgery
previous thymectomy within the past 3months
Lab requirements
Kidney function
egfr >= 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06765161 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD20 antibody, C5 complement inhibitor, plasma exchange disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify